Opinion: Who pays for Alberta’s dual-practice health care? - Edmonton Journal

Skip to Content Subscribe FAQ My Account Manage My Subscriptions News Local News Alberta Politics Health Local Crime True Crime National World Weather Archives Sports Edmonton Oilers Cult of Hockey NHL PWHL Junior Hockey NHL Edmonton Oil Kings Edmonton Elks CFL NFL Local Sports Soccer Golf Baseball Basketball Curling Opinion Columnists Letters Send a Letter to the Editor Malcolm Mayes editorial cartoons Business Local Business Featured Businesses Small Business Real Estate Commercial Real Estate Mortgages Energy Technology Gaming Internet Science Space FP Markets Alberta's Top Employers Arts Local Arts Theatre Music Festivals Books Movies Television TV Listings Celebrity Life Fashion & Beauty Homes First-Time Homebuyers Gardening Diet & Fitness Food Local food reviews Recipes Travel Travel Alberta Travel Canada Travel USA Travel International Cruises Travel Guide Savings Advice Contests National Contests Readers' Choice Special Sections EDMONTON FALL HOME SHOW Lives Told Tails Told Shopping Edmonton Journal Store Newsletters Puzzmo Vitality Alberta Work Well Diversions Puzzles New York Times Crossword Comics Horoscopes ePaper Driving Vehicle Research Reviews News Gear Guide

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.